Please assess the completion status of the following clinical trial:

Trial Title: Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with the following congenital heart lesions who require cardiopulmonary bypass for surgical repair or palliation will be eligible:~* D-transposition of the great vessels (D-TGA)~* Tetralogy of Fallot (TOF)~* Children of age less than 16 years~Exclusion Criteria:~* Signs of persistently elevated pulmonary vascular resistance preoperatively~* Cardiac arrest one week prior to surgery~* Prior surgical procedure that required use of cardio-pulmonary bypass~* Acute or chronic infection such as sepsis or wound infections~* History of any pulmonary condition such as pneumonia or respiratory distress syndrome~* Patients that have received steroid treatment within the last month~* DiGeorge syndrome~* Active bleeding disorder~* Any other condition associated with non-cardiac morbidity~* Use of another investigational drug~* Age over 16 years.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Nitric Oxide Delivery Group (Type: EXPERIMENTAL): Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
- Placebo (Type: NO_INTERVENTION): Placebo delivery of oxygen at standard dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).